Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Colorcon
McKesson
Covington
US Department of Justice
Argus Health
Queensland Health
Moodys
Johnson and Johnson
Farmers Insurance

Generated: February 21, 2018

DrugPatentWatch Database Preview

Claims for Patent: 7,973,040

« Back to Dashboard

Summary for Patent: 7,973,040
Title:Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
Abstract: The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections. ##STR00001##
Inventor(s): Harper; Steven (Rome, IT), Summa; Vincenzo (Rome, IT), Liverton; Nigel J. (Harleysville, PA), McCauley; John A. (Maple Glen, PA)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ) Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA (Rome, IT)
Application Number:12/504,955
Patent Claims: 1. A compound having the structure: ##STR00029## or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising an effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 2, further comprising a second therapeutic agent selected from the group consisting of a HCV protease inhibitor and a HCV NS5B polymerase inhibitor.

4. A method of treating a patient infected with HCV comprising the step of administering to said patient an effective amount of the compound according to claim 1.

5. A method of treating a patient infected with HCV comprising the step of administering to said patient an effective amount of the composition according to claim 2.

6. A method of treating a patient infected with HCV comprising the step of administering to said patient an effective amount of the composition according to claim 3.

7. A compound having structure: ##STR00030##

8. A pharmaceutical composition comprising an effective amount of the compound of claim 7 and a pharmaceutically acceptable carrier.

9. The pharmaceutical composition of claim 8, further comprising a second therapeutic agent selected from the group consisting of a HCV protease inhibitor and a HCV NS5B polymerase inhibitor.

10. A method of treating a patient infected with HCV comprising the step of administering to said patient an effective amount of the compound according to claim 7.

11. A method of treating a patient infected with HCV comprising the step of administering to said patient an effective amount of the composition according to claim 8.

12. A method of treating a patient infected with HCV comprising the step of administering to said patient an effective amount of the composition according to claim 9.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Julphar
Merck
Fish and Richardson
AstraZeneca
Argus Health
Deloitte
Covington
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot